Dr Reddy’s Stock Gets ‘Buy’ Call From Nomura; Brokerage Sees 26% Upside
Summary Brokerage firm Nomura has reiterated its positive outlook on Dr Reddy’s Stock and assigned a ‘Buy’ rating with a target price of ₹1,600. The optimistic view is driven by the company’s latest US product launch, exclusivity benefits, a growing oncology portfolio, and expectations of improved earnings visibility in the coming quarters. India’s pharmaceutical sector … Read more